Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Advanced Biomed Inc. Common Stock

Healthcare US ADVB

4.305USD
0.04(1.06%)

Last update at 2026-06-05T20:00:00Z

Day Range

4.144.39
LowHigh

52 Week Range

3.6148.80
LowHigh

Fundamentals

  • Previous Close 4.26
  • Market Cap6.82M
  • Volume6535
  • P/E Ratio1.42
  • Dividend Yield-%
  • EBITDA-2.97140M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM3.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.10152M -2.78228M -3.73278M -4.02772M -1.83716M
Minority interest - - - - -
Net income -0.10152M -2.78228M -3.73278M -4.02772M -1.83716M
Selling general administrative 2111.26M 1.26M 1.32M 0.62M 0.04M
Selling and marketing expenses - - - - -
Gross profit -0.01071M -0.01255M -0.01189M -0.00448M -0.00203M
Reconciled depreciation - 0.40M 0.37M 0.13M 0.06M
Ebit -0.10153M -2.54157M -3.07122M -2.37437M -1.83694M
Ebitda -0.09082M -2.14197M -2.70599M -2.24431M -1.77909M
Depreciation and amortization 0.01M 0.40M 0.37M 0.13M 0.06M
Non operating income net other - - - - -
Operating income -0.09411M -2.54157M -3.07122M -2.37437M -1.83694M
Other operating expenses 0.09M 2.54M 3.07M 2.37M 1.84M
Interest expense - - - - -
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 0.05M 0.02M 0.00024M 0.00003M
Net interest income - 0.05M 0.02M 0.00024M 0.00003M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.08M 2.54M 3.07M 2.37M 1.84M
Cost of revenue 0.01M 0.01M 0.01M 0.00448M 0.00203M
Total other income expense net -0.00741M -0.24071M -0.66155M -1.65335M -0.00022M
Discontinued operations - - - - -
Net income from continuing ops - -2.78228M -3.73278M -4.02772M -1.83716M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 6512.34M 4.46M 4.60M 6.71M 1.01M
Intangible assets - 0.12M 0.25M 0.41M -
Earning assets - - - - -
Other current assets 3128.65M 0.44M 0.16M 0.22M 0.85M
Total liab 3034.78M 2.80M 3.29M 3.22M 0.03M
Total stockholder equity 3477.56M 1.66M 1.31M 3.49M 0.98M
Deferred long term liab - - - - -
Other current liab 2887.99M 2.05M 2.42M 1.98M 0.02M
Common stock 21.64M 0.02M 0.02M 0.10M 0.01M
Capital stock - 0.02M 0.02M 0.10M 0.01M
Retained earnings -19233.04400M -15.97407M -13.19180M -9.45902M -5.43130M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 2903.91M 2.61M 2.62M 4.78M 0.07M
Cash and equivalents - - - - -
Total current liabilities 2889.13M 2.73M 3.28M 2.99M 0.03M
Current deferred revenue - - - - -
Net debt -2902.65017M -2.47932M -2.37995M -4.30704M -0.05871M
Short term debt 1.12M 0.06M 0.22M 0.24M 0.00543M
Short long term debt - - - - -
Short long term debt total 1.26M 0.13M 0.24M 0.48M 0.00721M
Other stockholder equity 21348.01M 16.49M 13.67M 12.58M 6.57M
Property plant equipment - - - - -
Total current assets 6032.57M 3.05M 2.79M 5.01M 0.91M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.00796M 0.00632M 0.00481M 0.16M 0.00042M
Long term debt - - - - -
Inventory - -0.00632M - - -
Accounts payable 0.02M 0.62M 0.63M 0.76M 0.00019M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1341.69M 1.12M 0.80M 0.27M -0.17709M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 414.37M 0.64M 0.61M 0.07M -
Deferred long term asset charges - - - - -
Non current assets total 479.77M 1.41M 1.81M 1.71M 0.09M
Capital lease obligations - 0.13M 0.24M 0.47M 0.00702M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.07411M -0.26301M -1.08368M -0.02544M
Change to liabilities - - - - -
Total cashflows from investing activities -0.00098M -0.07411M -0.26301M -1.08368M -0.02544M
Net borrowings - 1.66M 0.00000M - -
Total cash from financing activities 0.18M 1.87M 0.46M 6.10M 0.70M
Change to operating activities - - - - -
Net income -0.10152M -2.78228M -3.73278M -4.02772M -1.83716M
Change in cash 0.02M -0.01431M -2.16159M 4.72M 0.00022M
Begin period cash flow 0.08M 2.62M 4.78M 0.07M 0.07M
End period cash flow 0.10M 2.61M 2.62M 4.78M 0.07M
Total cash from operating activities -0.18146M -2.12634M -2.96362M -0.74145M -0.47397M
Issuance of capital stock - 0.00000M 1.01M 6.10M 0.70M
Depreciation 0.01M 0.40M 0.37M 0.13M 0.06M
Other cashflows from investing activities - - -0.00164M -0.39362M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - 0.05M 0.02M 0.00024M 0.00003M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 0.21M -0.55347M - -
Change to netincome - - - - -
Capital expenditures 0.00098M 0.07M 0.21M 1.31M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.09065M 0.26M 0.25M 1.50M 1.31M
Stock based compensation - - - - -
Other non cash items 2915.05M -0.05350M 0.15M 1.66M -0.00003M
Free cash flow -0.18245M -2.20045M -3.17615M -2.05358M -0.49942M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
ADVB
Advanced Biomed Inc. Common Stock		 0.04 1.06% 4.30 1.42 - - 0.72
TMO
Thermo Fisher Scientific Inc		 -9.23 1.91% 472.80 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -2.34 1.25% 184.30 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -2.93 2.12% 135.44 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -2.58 0.46% 562.16 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Advanced Biomed Inc. Common Stock

122 East 42nd Street, New York, NY, United States, 10168

Key Executives

Name Title Year Born
Dr. Yi Lu Ph.D. CEO & Chairman 1965
Mr. Mingze Yin CFO & Director 1990
- Alan Director of Investor Relations NA
Dr. Hung To Pau Ph.D. Secretary 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions